Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Bank of New York Mellon Corp Boosts Position in Blueprint Medicines Corp (NASDAQ:BPMC)
10:06am, Wednesday, 08'th Apr 2020
Bank of New York Mellon Corp grew its holdings in Blueprint Medicines Corp (NASDAQ:BPMC) by 1.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission
AQR Capital Management LLC Acquires 3,112 Shares of Blueprint Medicines Corp (NASDAQ:BPMC)
09:12am, Wednesday, 08'th Apr 2020
AQR Capital Management LLC increased its holdings in shares of Blueprint Medicines Corp (NASDAQ:BPMC) by 34.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1
Norges Bank Acquires New Shares in Blueprint Medicines Corp (NASDAQ:BPMC)
10:42am, Tuesday, 07'th Apr 2020
Norges Bank acquired a new stake in shares of Blueprint Medicines Corp (NASDAQ:BPMC) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 997,612 shares of the b
Cubist Systematic Strategies LLC Buys 2,540 Shares of Blueprint Medicines Corp (NASDAQ:BPMC)
09:08am, Monday, 06'th Apr 2020
Cubist Systematic Strategies LLC boosted its stake in Blueprint Medicines Corp (NASDAQ:BPMC) by 25.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange C
Stocks To Watch: OPEC Goes Virtual
01:04pm, Saturday, 04'th Apr 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
7 Promising Biotech Stocks in a Postpandemic World
10:34pm, Friday, 03'rd Apr 2020
Casdin Capital’s Eli Casdin highlights seven promising life-sciences stocks, including bluebird bio, Invitae, and Crispr Therapeutics
Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better
01:37pm, Friday, 03'rd Apr 2020
Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.
Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More
12:21pm, Friday, 03'rd Apr 2020
The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3
Blueprint's Avapritinib Shows Promise For Indolent Systemic Mastocytosis
10:37pm, Thursday, 02'nd Apr 2020
Blueprint's avapritinib may have another blockbuster indication in the making: indolent systemic mastocytosis. Avapritinib efficacy and safety profile in this p
Wall Street Analysts Are Bullish on Top Healthcare Picks
05:06pm, Thursday, 02'nd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Ascendis Pharma (ASND) and
BRIEF-Blueprint Medicines Announces Achievement Of Key Portfolio Milestones
12:54pm, Wednesday, 01'st Apr 2020
Blueprint Medicines Corp:
Blueprint Medicines' pralsetinib shows positive action in RET-altered thyroid cancer
12:51pm, Wednesday, 01'st Apr 2020
Blueprint Medicines (NASDAQ:BPMC) announces a pipeline update including topline data from the Phase 1/2 ARROW study evaluating pralsetinib (BLU-667) in patients with solid tumors.In patients with RET-
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
12:00pm, Wednesday, 01'st Apr 2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key miles
XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
02:32pm, Tuesday, 31'st Mar 2020
S&P Biotech ETF (XBI) slumped -20% year-to-date, in-line with the S&P 500, due to the unrelenting coronavirus pandemic,. Heavy exposure to small caps contribute
Week In Review: Abbisko Raises $70 Million To Develop Cancer Drug Candidates
09:12am, Monday, 30'th Mar 2020
Laekna Therapeutics Shanghai acquired global rights to Novartis' anti-PD-L1 antibody. Tyligand Bioscience acquired exclusive China rights to onapristone ER from
